{"id":"temozolomide-tmz","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Myelosuppression (thrombocytopenia, neutropenia)"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Headache"},{"rate":"20-30","effect":"Constipation"},{"rate":"20-25","effect":"Anemia"},{"rate":"5-10","effect":"Opportunistic infections (PCP)"}]},"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TMZ is a prodrug that is converted to its active form, MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide), which methylates DNA and triggers apoptosis in rapidly dividing cells. It crosses the blood-brain barrier effectively, making it particularly useful for brain tumors. The drug is cell-cycle nonspecific and causes cumulative DNA damage leading to cancer cell death.","oneSentence":"Temozolomide is an alkylating agent that methylates DNA at the O6 position of guanine, causing DNA strand breaks and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:56.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme (newly diagnosed and recurrent)"},{"name":"Anaplastic astrocytoma (recurrent)"},{"name":"Melanoma (metastatic)"}]},"trialDetails":[{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT04019002","phase":"PHASE1","title":"Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma","status":"COMPLETED","sponsor":"Susan Chang","startDate":"2019-11-19","conditions":"Glioblastoma Multiforme (GBM)","enrollment":17},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT05691491","phase":"PHASE1, PHASE2","title":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-28","conditions":"Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm","enrollment":58},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT03528642","phase":"PHASE1","title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-01","conditions":"Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3","enrollment":40},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT07485049","phase":"EARLY_PHASE1","title":"Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors","status":"NOT_YET_RECRUITING","sponsor":"Nader Sanai","startDate":"2026-04","conditions":"Glioblastoma (GBM)","enrollment":78},{"nctId":"NCT05843253","phase":"PHASE2","title":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-08-22","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":120},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03663725","phase":"PHASE3","title":"Treatment Intensification With Temozolomide in Adults With a Glioblastoma","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-13","conditions":"Glioblastoma","enrollment":486},{"nctId":"NCT07476794","phase":"PHASE2","title":"Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-11-01","conditions":"Glioblastoma","enrollment":118},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Glioblastoma","enrollment":65},{"nctId":"NCT06478212","phase":"PHASE1, PHASE2","title":"Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2025-01-22","conditions":"IDH1-mutant Glioma, IDH2-mutant Glioma","enrollment":51},{"nctId":"NCT03749187","phase":"PHASE1","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2019-04-03","conditions":"Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation","enrollment":78},{"nctId":"NCT04457284","phase":"PHASE2","title":"Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-18","conditions":"Colorectal Adenocarcinoma","enrollment":18},{"nctId":"NCT03257618","phase":"NA","title":"Quality of Life and Neurocognitive Functioning","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-07-27","conditions":"Glioma","enrollment":26},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT04919382","phase":"PHASE2","title":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2022-01-26","conditions":"Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":56},{"nctId":"NCT06681220","phase":"PHASE1, PHASE2","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-23","conditions":"Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT07104032","phase":"PHASE3","title":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-03","conditions":"Relapsed/Refractory Primary Central Nervous System Lymphoma","enrollment":132},{"nctId":"NCT06504381","phase":"PHASE1, PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":"High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma","enrollment":70},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT07452458","phase":"PHASE3","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2026-06-08","conditions":"Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma","enrollment":398},{"nctId":"NCT06546631","phase":"","title":"Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients","status":"RECRUITING","sponsor":"University College Cork","startDate":"2024-08-22","conditions":"Glioma","enrollment":55},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT07195591","phase":"PHASE3","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","status":"RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2025-12-10","conditions":"Glioblastoma","enrollment":766},{"nctId":"NCT03519412","phase":"PHASE2","title":"Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status","status":"COMPLETED","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2019-01-23","conditions":"Colorectal Neoplasms, Microsatellite Instability","enrollment":107},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT05765812","phase":"PHASE1, PHASE2","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-15","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III","enrollment":116},{"nctId":"NCT06346067","phase":"PHASE3","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2024-04-29","conditions":"Advanced or Metastatic NRAS-mutant Melanoma","enrollment":78},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT01824875","phase":"PHASE2","title":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-08-08","conditions":"Gastrinoma, Glucagonoma, Insulinoma","enrollment":144},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT02942264","phase":"PHASE1, PHASE2","title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-12-14","conditions":"Brain Tumor, Astrocytoma, Astroglioma","enrollment":53},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06448286","phase":"PHASE3","title":"PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-12-01","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT05095376","phase":"PHASE3","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-28","conditions":"Glioblastoma, Gliosarcoma","enrollment":265},{"nctId":"NCT04765514","phase":"PHASE2","title":"Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2022-07-27","conditions":"Glioblastoma Multiforme","enrollment":107},{"nctId":"NCT03529448","phase":"PHASE1, PHASE2","title":"TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2023-08-18","conditions":"Glioblastoma","enrollment":33},{"nctId":"NCT03830918","phase":"PHASE1, PHASE2","title":"Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-03-06","conditions":"Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":59},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT04901702","phase":"PHASE1, PHASE2","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-06-09","conditions":"Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":90},{"nctId":"NCT03405792","phase":"PHASE2","title":"Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-23","conditions":"Glioblastoma, Glioblastoma, WHO Grade IV","enrollment":40},{"nctId":"NCT07391215","phase":"PHASE1, PHASE2","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2026-01-19","conditions":"Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)","enrollment":64},{"nctId":"NCT05635734","phase":"PHASE1, PHASE2","title":"Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cantex Pharmaceuticals","startDate":"2023-09-05","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT07389278","phase":"PHASE1, PHASE2","title":"Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)","status":"NOT_YET_RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2026-03-09","conditions":"Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma","enrollment":97},{"nctId":"NCT05739942","phase":"PHASE1","title":"Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-05-15","conditions":"Newly Diagnosed and Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT06388733","phase":"PHASE3","title":"A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma","status":"RECRUITING","sponsor":"Ivy Brain Tumor Center","startDate":"2024-06-19","conditions":"Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant","enrollment":450},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":"Glioblastoma","enrollment":170},{"nctId":"NCT05432791","phase":"PHASE2, PHASE3","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-30","conditions":"Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":73},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT06208657","phase":"PHASE1, PHASE2","title":"Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer","status":"RECRUITING","sponsor":"Australian & New Zealand Children's Haematology/Oncology Group","startDate":"2024-07-10","conditions":"Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor","enrollment":90},{"nctId":"NCT07365280","phase":"PHASE2","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"ZSky Biotech Inc","startDate":"2026-01-09","conditions":"Glioblastoma","enrollment":78},{"nctId":"NCT04752813","phase":"PHASE2","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BPGbio","startDate":"2022-08-22","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":"Glioma","enrollment":10},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT06630260","phase":"PHASE1, PHASE2","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2024-11-15","conditions":"Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":182},{"nctId":"NCT07349693","phase":"PHASE2, PHASE3","title":"Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Everfront Biotech Co., Ltd.","startDate":"2026-11-01","conditions":"Recurrent Glioblastoma, IDH-Wildtype","enrollment":175},{"nctId":"NCT07346157","phase":"PHASE1, PHASE2","title":"Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease","status":"NOT_YET_RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2026-03-01","conditions":"Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent","enrollment":69},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05236036","phase":"PHASE1","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-08","conditions":"Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype","enrollment":60},{"nctId":"NCT02179086","phase":"PHASE2","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-12-04","conditions":"Glioblastoma","enrollment":606},{"nctId":"NCT04623931","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-01-30","conditions":"Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma","enrollment":40},{"nctId":"NCT05588453","phase":"PHASE1, PHASE2","title":"Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain","status":"RECRUITING","sponsor":"Kari Kendra","startDate":"2023-03-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma","enrollment":30},{"nctId":"NCT07334301","phase":"PHASE1, PHASE2","title":"A Multi-Arm, Platform Trial For Relapsed Neuroblastoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-11-11","conditions":"Relapsed Neuroblastoma","enrollment":160},{"nctId":"NCT06095375","phase":"PHASE1","title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2022-07-04","conditions":"Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma","enrollment":21},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT04200443","phase":"PHASE2","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-01-14","conditions":"Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":72},{"nctId":"NCT02617745","phase":"PHASE2","title":"Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2015-11-30","conditions":"Glioblastoma","enrollment":244},{"nctId":"NCT04677049","phase":"PHASE1, PHASE2","title":"Study of Niacin in Glioblastoma","status":"SUSPENDED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-18","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","enrollment":59},{"nctId":"NCT06625047","phase":"PHASE4","title":"Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-10-07","conditions":"Astrocytoma, IDH-Mutant, Glioblastoma, Glioma","enrollment":30},{"nctId":"NCT06991101","phase":"PHASE2","title":"Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2025-12-03","conditions":"Glioblastoma, Brain Cancer, Glioblastoma Multiforme","enrollment":190},{"nctId":"NCT04796012","phase":"PHASE1, PHASE2","title":"VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Solid Tumor, Rhabdomyosarcoma","enrollment":23},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":"Malignant Melanoma","enrollment":29},{"nctId":"NCT06410248","phase":"PHASE1","title":"Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2024-07-23","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma","enrollment":30},{"nctId":"NCT01858168","phase":"PHASE1","title":"Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07-01","conditions":"Ewing Sarcoma, Rhabdomyosarcoma","enrollment":49},{"nctId":"NCT03728361","phase":"PHASE2","title":"Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dwight Owen","startDate":"2018-12-31","conditions":"Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma","enrollment":55},{"nctId":"NCT05040360","phase":"PHASE2","title":"Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-05-05","conditions":"Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":141},{"nctId":"NCT04019327","phase":"PHASE1, PHASE2","title":"A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-11","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":16},{"nctId":"NCT02344355","phase":"PHASE2","title":"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2017-03-13","conditions":"Glioblastoma Multiforme","enrollment":90},{"nctId":"NCT04339036","phase":"PHASE2","title":"CapTemY90 for Grade 2/3 NET Liver Metastases","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-10-07","conditions":"Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT03212742","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2017-09-04","conditions":"Malignant Gliomas, Radiotherapy, PARP Inhibitor","enrollment":91},{"nctId":"NCT03880019","phase":"PHASE2","title":"A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-19","conditions":"Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4451,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temodar","CCRG-81045","Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-","M & B 39831","M and B 39831"],"phase":"phase_3","status":"active","brandName":"Temozolomide (TMZ)","genericName":"Temozolomide (TMZ)","companyName":"Institut de Recherches Internationales Servier","companyId":"institut-de-recherches-internationales-servier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is a small molecule DNA inhibitor used to treat conditions such as glioblastoma, malignant glioma, and brain and central nervous system tumors. It is typically administered in conjunction with radiotherapy as part of the treatment regimen for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}